IntelGenx Technologies Corp. (IGXT) EPS Estimated At $-0.01; BioDelivery Sciences International, Inc. (BDSI) Covered By 6 Bulls

July 26, 2017 - By Ellis Scott

Among 6 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery Sciences International had 17 analyst reports since August 16, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Friday, May 26. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, June 23. H.C. Wainwright has “Buy” rating and $400 target. On Wednesday, May 11 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. FBR Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Tuesday, November 10 with “Mkt Perform” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, July 24. Cantor Fitzgerald initiated BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Wednesday, November 4 with “Buy” rating. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, June 9. H.C. Wainwright has “Buy” rating and $400 target. Cantor Fitzgerald upgraded the stock to “Overweight” rating in Wednesday, May 17 report. Janney Capital upgraded the shares of BDSI in report on Friday, September 23 to “Buy” rating. Piper Jaffray maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Monday, July 10 with “Buy” rating. See BioDelivery Sciences International, Inc. (NASDAQ:BDSI) latest ratings:

24/07/2017 Broker: Janney Capital Rating: Buy New Target: $4.0000
24/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
10/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0000 Maintain
23/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
21/06/2017 Broker: FBR Capital Rating: Buy Maintain
09/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
26/05/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Initiate
17/05/2017 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Upgrade

Analysts expect IntelGenx Technologies Corp. (OTCMKTS:IGXT) to report $-0.01 EPS on August, 10.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, IntelGenx Technologies Corp.’s analysts see 0.00% EPS growth. About 137,098 shares traded. IntelGenx Technologies Corp. (OTCMKTS:IGXT) has 0.00% since July 26, 2016 and is . It has underperformed by 16.70% the S&P500.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The company has market cap of $181.37 million. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. It currently has negative earnings. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction.

About 363,753 shares traded. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 24.37% since July 26, 2016 and is uptrending. It has outperformed by 7.67% the S&P500.

Since January 30, 2017, it had 0 insider buys, and 8 selling transactions for $596,528 activity. 530 shares were sold by Vasisht Niraj, worth $1,007 on Friday, March 24. ODONNELL FRANCIS E JR had sold 750 shares worth $1,425 on Wednesday, March 22. De Paolantonio Ernest Robert also sold $38,923 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Wednesday, February 22. Another trade for 110,895 shares valued at $210,920 was made by Sirgo Mark A on Wednesday, March 15.

Investors sentiment decreased to 0.75 in Q4 2016. Its down 0.07, from 0.82 in 2016Q3. It is negative, as 17 investors sold BioDelivery Sciences International, Inc. shares while 19 reduced holdings. 9 funds opened positions while 18 raised stakes. 20.48 million shares or 22.10% less from 26.28 million shares in 2016Q3 were reported. Geode Capital Mngmt Limited Co invested 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Illinois-based Archford Strategies Ltd Liability Com has invested 0.03% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Goldman Sachs Group owns 80,544 shares for 0% of their portfolio. New York-based Morgan Stanley has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Venbio Select Advisor Limited Liability Company invested in 644,176 shares or 0.23% of the stock. Price T Rowe Associates Incorporated Md holds 0% or 31,500 shares. Northern Tru reported 130,058 shares. Susquehanna Limited Liability Partnership stated it has 24,659 shares. Moreover, Credit Suisse Ag has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 73,233 shares. Us Bancshares De accumulated 500 shares or 0% of the stock. State Street invested in 51,562 shares or 0% of the stock. 238,000 are held by Deutsche Comml Bank Ag. Tiverton Asset Mngmt Ltd Llc reported 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Blackrock Advsr Limited Liability Corporation holds 0% or 8,009 shares in its portfolio. Valley Advisers reported 4,215 shares.

IntelGenx Technologies Corp is a Canada drug delivery firm focused on the development of oral immediate-release and controlled-release products and on developing pharmaceutical products based on its drug delivery technologies. The company has market cap of $71.74 million. The Company’s product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology. It currently has negative earnings. The VersaFilm technology consists of a thin polymeric film consisting of the United States Pharmacopeia (USP) components for use in food, pharmaceutical and cosmetic products.